Avedro announced the launch and shipment of Photrexa Viscous and Photrexa, two FDA-approved drugs used in corneal collagen cross-linking procedures with the KXL System.
In April, the FDA approved Photrexa Viscous, Photrexa and the KXL System to be used in cross-linking for the treatment of progressive keratoconus. The second indication for the products, for the treatment of corneal ectasia following refractive surgery, received FDA approval in July.
“We are proud to announce that FDA-approved cross-linking treatments are now a reality, and our Photrexa drug products are now available. Clinicians have already started to treat their patients in the U.S. who are suffering from progressive keratoconus or corneal ectasia,” Reza Zadno, PhD, CEO of Avedro, said in a company press release.
This is the only corneal collagen cross-linking therapy approved by the FDA.